Amneal Pharmaceuticals (AMRX) Profit After Tax (2017 - 2026)

Amneal Pharmaceuticals' Profit After Tax history runs 10 years deep, the most recent figure standing at $78.0 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 216.84% year-over-year to $78.0 million; the TTM figure through Mar 2026 stood at $209.5 million (up 1079.75% YoY), while the FY2025 annual figure was $127.9 million, up 209.45% from the prior year.
• Profit After Tax was $78.0 million for Q1 2026 at Amneal Pharmaceuticals, down from $91.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $91.0 million in Q4 2025 to a low of -$242.1 million in Q2 2022.
• Historically, Profit After Tax has averaged -$12.7 million across 5 years, with a median of $6.0 million in 2024.
• Biggest YoY gain for Profit After Tax was 505.1% in 2023; the steepest drop was 1584.0% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$5.9 million in 2022, then slumped by 1584.0% to -$98.6 million in 2023, then surged by 35.37% to -$63.8 million in 2024, then jumped by 242.67% to $91.0 million in 2025, then decreased by 14.24% to $78.0 million in 2026.
• The last three Profit After Tax figures came in at $78.0 million (Q1 2026), $91.0 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.